Showing results (571-580 of 1,134) with videos related to

Sort By:
Pageof 114
Human Genetics|December 1, 1994
Genetic heterogeneity of severe von Willebrand disease type III in the German populationR Schneppenheim, S Krey, F Bergmann, et al.
Cancer Letters|February 5, 2003
Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancerTasha R Smith, Mark Steven Miller, Kurt Lohman, et al.
International Journal of Clinical Practice|May 9, 2021
Imaging approach to COVID-19 associated pulmonary embolismLukas M Trunz, Patrick Lee, Steven M Lange, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 4, 2000
The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancerE M Lange, H Chen, K Brierley, et al.
Neurology|February 1, 1995
Autosomal dominant, familial spastic paraplegia, type I: clinical and genetic analysis of a large North American familyJ K Fink, G B Sharp, B M Lange, et al.
Chemistry, an Asian Journal|March 9, 2017
C=C π Bond Modified Graphitic Carbon Nitride Films for Enhanced Photoelectrochemical Cell PerformanceJuncao Bian, Lifei Xi, Jianfu Li, et al.
Scientific Reports|July 6, 2021
Enzymatic liver function measured by LiMAx is superior to current standard methods in predicting transplant-free survival after TIPS implantationJassin Rashidi-Alavijeh, Alisan Kahraman, Guido Gerken, et al.
European Journal of Gastroenterology & Hepatology|August 24, 2010
Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirinChristian M Lange, Michael von Wagner, Jörg Bojunga, et al.
International Journal of Radiation Oncology, Biology, Physics|April 7, 1999
Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: implications in the inoperable and three-dimensional dose-escalation settingsT E Sawyer, J A Bonner, P M Gould, et al.
Journal of Neuroimmunology|January 15, 2000
Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudineR H Enting, N A Foudraine, J M Lange, et al.
Pageof 114